Cargando…

Targeted therapies in breast cancer: are heart and vessels also being targeted?

The concept of 'targeted' therapies implies that such drugs only act on cells that specifically express the particular target, therefore giving rise to a low incidence of side effects. However, targeted therapies currently approved for the treatment of breast cancer have demonstrated a rel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Criscitiello, Carmen, Metzger-Filho, Otto, Saini, Kamal S, de Castro Jr, Gilberto, Diaz, Marie, La Gerche, André, de Azambuja, Evandro, Piccart-Gebhart, Martine J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446327/ https://www.ncbi.nlm.nih.gov/pubmed/22713170 http://dx.doi.org/10.1186/bcr3142

Ejemplares similares

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
por: Rossari, José R., et al.
Publicado: (2012)

Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25
por: Pinto, Ana Catarina, et al.
Publicado: (2014)

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
por: Snoj, Natasa, et al.
Publicado: (2009)

Targeting immune checkpoints in breast cancer: an update of early results
por: Solinas, Cinzia, et al.
Publicado: (2017)

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
por: Caparica, Rafael, et al.
Publicado: (2019)

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA
por: Ades, Felipe, et al.
Publicado: (2017)

New generation of breast cancer clinical trials implementing molecular profiling
por: Zardavas, Dimitrios, et al.
Publicado: (2016)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
por: Lambertini, Matteo, et al.
Publicado: (2020)

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
por: de Azambuja, E, et al.
Publicado: (2007)

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer
por: Maurer, Christian, et al.
Publicado: (2018)

Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer
por: Metzger-Filho, Otto, et al.
Publicado: (2013)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

Treatment of early-stage HER2+ breast cancer—an evolving field
por: Ferreira, Arlindo R, et al.
Publicado: (2015)

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
por: Brandão, Mariana, et al.
Publicado: (2020)

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma
por: Ades, Felipe, et al.
Publicado: (2012)

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
por: Preusser, Matthias, et al.
Publicado: (2018)

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
por: Fernández-Cuesta, Lynnette, et al.
Publicado: (2012)

Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment
por: Nader-Marta, Guilherme, et al.
Publicado: (2023)

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies
por: Saini, Kamal S., et al.
Publicado: (2020)

Immunotherapy in breast cancer: an overview of current strategies and perspectives
por: Debien, Véronique, et al.
Publicado: (2023)

Evolution-Based Drug Discovery: Antifungal Also Disrupts Blood Vessel Formation
por: Mejia, Robin
Publicado: (2012)

Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy
por: Lambertini, Matteo, et al.
Publicado: (2022)

Adenoid cystic carcinoma of the breast – an aggressive presentation with pulmonary, kidney, and brain metastases: a case report
por: Mhamdi, Hasnae Alaoui, et al.
Publicado: (2017)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

I-SPY 2: optimising cancer drug development in the 21st century
por: Bartsch, Rupert, et al.
Publicado: (2016)

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2016)

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
por: Saini, Kamal S., et al.
Publicado: (2020)

Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection
por: Criscitiello, Carmen, et al.
Publicado: (2010)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis
por: Tagliamento, Marco, et al.
Publicado: (2021)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
por: Franzoi, Maria Alice, et al.
Publicado: (2020)

Determinants of Vessel Targeting in Vasculitis
por: Hoffman, Gary S.
Publicado: (2004)

Emerging issues related to COVID-19 vaccination in patients with cancer
por: Saini, Kamal S., et al.
Publicado: (2021)

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis
por: Martins-Branco, Diogo, et al.
Publicado: (2022)

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Challenges in launching multinational oncology clinical trials in India
por: Saini, Kamal S., et al.
Publicado: (2013)

Case of Fatal Purpura Associated with Waxy Degeneration of the Striated Muscles, and Also of the Vessels in the Affected Parts
por: Fox, Wilson
Publicado: (1865)

Phosphoethanolamine and the danger of unproven drugs
por: Pondé, Noam, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nbc4eio7cebvmvi9avn3f1llhr